{"id":"W3213271278","doi":"10.1182/blood-2021-154022","title":"Updated Results from a Phase II Study of Hyper-CVAD with Sequential Blinatumomab in Adults with Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"","keywords":"Blinatumomab; Medicine; Minimal residual disease; Internal medicine; Rituximab; Cytarabine; Oncology; Chemotherapy; Acute lymphocytic leukemia; Maintenance therapy; Gastroenterology; Leukemia; Immunology; Pediatrics; Lymphoblastic Leukemia; Lymphoma","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004941196,0.0007933662,0.001772148,0.0002643696,0.0003076823,0.001112476,0.0007391396,0.0007382118,0.001798447],"category_scores_gemma":[0.002217285,0.0003568374,0.001040848,0.000518368,0.0004893934,0.0007849326,0.0004329075,0.001757836,0.0005294479],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006812474,"about_ca_system_score_gemma":0.001180075,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001305941,"about_ca_topic_score_gemma":0.002491943,"domain_scores_codex":[0.9987451,0.0007249271,0.0001214454,0.0001222445,0.0001431436,0.0001431653],"domain_scores_gemma":[0.9978372,0.0005789234,0.000501582,0.0001888534,0.0002403619,0.0006530157],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5090446,0.03520285,0.1077017,0.001798317,0.006478774,0.0006347967,0.0006715118,0.00417087,0.04736669,0.0002974486,0.01029212,0.2763403],"study_design_scores_gemma":[0.2705175,0.4698422,0.2234945,0.0001856005,0.005445648,0.001658622,0.0002556038,0.00183778,0.007519919,0.0003790572,0.01879874,0.00006473299],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9840685,0.007093208,0.001099898,0.0006332211,0.0001031373,0.001529607,0.003459953,0.000072565,0.001939975],"genre_scores_gemma":[0.9824075,0.003230844,0.002327756,0.001214291,0.0001333378,0.001554476,0.008179334,0.00003293449,0.0009194172],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004941196,"threshold_uncertainty_score":0.02613187,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01257834677322908,"score_gpt":0.2672741256543651,"score_spread":0.254695778881136,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}